Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MLSCI330 Hematology > Coagulation Testing, Disorders, Treatment > Flashcards

Coagulation Testing, Disorders, Treatment Flashcards

1
Q

PT (Prothrombin Time): Purpose

A

identifies deficiency in EXTRINSIC + COMMON pathway (fibrinogen, II/ prothrombin, V, VII, X)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The PT reagent contains (3)

A

thromboplastin, phospholipid, and calcium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

PTT (Partial Thromboplastin Time): Purpose

A
  • identifies deficiency in INTRINSIC + COMMON pathway (all factors except VII and XIII)
  • monitors unfractioned heparin treatment + some thrombin inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mixing Studies: Purpose

A

Determines if abnormal PT/PTT is due to factor deficiency OR an inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mixing Studies: Principle

A
  • mix patient plasma + normal control (has all coag factors)
  • test PT or PTT

Corrected = factor deficiency
Uncorrected = perform inhibitor screen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Inhibitor Screen: Purpose

A

Determines if inhibitor is immediate OR delayed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Inhibitor Screen: Principle

A
  • (In 1:1 AND 4:1 patient ratios) = mix patient plasma + Normal control (has all coag factors)
  • test PT/ PTT 3 times:
    1. Mixed: Immediately
    2. Mixed: after 1 HOUR of incubation at 37 degrees
    3. Separately: after 1 HOUR of incubation at 37 degrees
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What does it mean if PT/PTT of an inhibitor screen is prolonged immediately after patient plasma + Normal control are mixed ?

A
  • Inhibitor screen = POS
  • Inhibitor reacts IMMEDIATELY
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does it mean if PT/PTT of an inhibitor screen is prolonged after 1 HOUR of (patient plasma + Normal control) being mixed when it was normal after being immediately mixed ?

A
  • Inhibitor screen = POS
  • Inhibitor is delayed reacting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How can heparin be removed before performing an inhibitor screen ? Why is this done ?

A
  • remove Heparin using Hepzyme
  • Heparin causes FALSE POS inhibitor screen
  • prolongs PT/ PTT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Why is patient plasma and Normal control incubated SEPARATELY for 1 hour at 37 degrees as part of the Inhibitor Screen ? What should the results be ?

A
  • separate incubation ensures clotting factors did not degrade during incubation
  • Normal control = POS
  • patient plasma = neg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why does the inhibtor screen use 1:1 AND 4:1 patient to Normal control ratios ?

A

4:1 ratio increases sensitivity to inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Single Factor Assay: Purpose

A

Determines which factor(s) patient is deficient in

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Single Factor Assay: Principle

A
  • mix patient plasma + plasma deficient in a single factor
  • test PT or PTT
  • compare results to standard graph to determine factor concentration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

If patient plasma corrects PT/ PTT in a Single Factor Assay, what does this mean ?

A

Recall: patient plasma + plasma deficient in a known factor are mixed

Corrected = patient corrects deficient plasma; patient is not deficient in particular factor

Uncorrected = patient unable to correct deficient plasma; patient is deficient in the same known factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Fibrinogen Testing: Purpose

A

Determines levels of fibrinogen in plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Fibrinogen Testing: Principle

A
  • EXCESS thrombin + patient sample
  • level of plasma fibrinogen is INVERSELY proportional to clotting time

NOTE: excess thrombin neutralizes anti-thrombin activity (FDPs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Why is thrombin added in EXCESS in fibrinogen testing ?

A

To neutralize anti-thrombin activity (ie. FDPs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

TT (Thrombin Time): Purpose

A
  • Detect DECREASED levels of fibrinogen, DYSFIBRINOGENEMIA, or THROMBIN INHIBITORS (ie. FDPs, D-dimers)
  • Monitor/ evaluate DIC, heparin therapy, fibrinogen diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

TT: Principle

A

Thrombin Time:
- dilute BOVINE thrombin + patient sample to bypass previous steps of coag cascade
- measures time to convert fibrinogen to insoluble fibrin crosslinks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

D-Dimer: Purpose

A

To rule out DIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

D-Dimer: Principle

A
  • turbidimetric IMMUNOASSAY (DIRECTLY proportional)
  • MONOCLONAL Abs specific to D-dimers coat latex particles
  • D-dimers DIRECTLY bind to Abs = AGGLUTINATION = increased turbidity = INCREASED ABSORBANCE measured
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Reptilase Time: Purpose

A

To detect HEPARIN, DYSFIBRINOGENEMIA, or FIBRINOGEN DEFICIENCY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Reptilase Time: Principle

A

reptilase (enzyme) = converts fibrinogen to fibrin + NOT INHIBITED by heparin = clot forms
- compares results to PROLONGED thrombin time (TT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What does it mean if TT = prolonged and Reptilase Time = equally prolonged ?

A

Fibrinogen Deficiency
- there is no fibrinogen in the first place; reptilase cannot form fibrin

NOTE = prolonged TT cannot be due to heparin because reptilase is not affected by heparin, which is also prolonged in this case

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What does it mean if TT = prolonged and Reptilase Time = MORE PROLONGED ?

A

DYSFIBRINOGENEMIA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What does it mean if TT = prolonged and Reptilase Time = NORMAL ?

A

HEPARIN is present
- but reptilase is unaffected by the anticoagulant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Bleeding Time: Purpose

A

To test ability of PLTs to undergo PRIMARY HEMOSTASIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Bleeding Time: Principle

A
  • IN VIVO
  • DO NOT DO if PLT <80 x10^9/L
  • shallow skin-wound is made on patient
  • time to stop bleeding is measured
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Which coagulation tests use Turbidimetric end-point clot detection ?

A
  • PT
  • PTT
  • TT
  • Fibrinogen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Platelet Aggregometry: Purpose

A

To assess PLT function (secretion, aggregation, adhesion w/ ristocetin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Platelet Aggregometry: Principle

A
  • DO NOT DO if PLT <50 x10^9/L
  • PLT-RICH plasma is stirred in AGGREGOMETER with diff agonists:
    1. ADP + collagen + EPO + arachidonic acid = tests GPIIb/ IIIa and fibrinogen function
    2. Ristocetin = tests GPIb and vWF function

NOTE: agonists initiate PLT aggregometry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Interferences in PLT Aggregometry

A
  • gross lipemia
  • aspirin
  • PLT <50 x10^9/L
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Ristocetin Co-factor Assay: Purpose

A
  • To ensure vWF is present for coagulation
  • Differentiate VonWillebrand Disease from Bernard Soulier
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Ristocetin Co-factor Assay: Principle

A
  • mix patient plasma with Normal PLTs + Ristocetin
  • Ristocetin induces vWF to attach to GPIb receptors on Normal PLTs = aggregation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

How to differentiate Unfractioned Heparin (UFH) from Low Molecular Weight Heparin (LMWH) ?

A

Both:
- indirect anticoagulants

UFH:
- inhibits all serine proteases (plasmin, IIa, IXa, Xa, XIa, XIIa) EXCEPT VII and Kallikrein
- monitored by aPTT or anti-Xa assay

LMWH:
- inhibits Xa
- monitored by anti-Xa assay ONLY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Heparin is a cofactor of __.

A

Heparin is a cofactor of ANTI-THROMBIN.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Coumadin: what does it do ? How is it monitored ?

A
  • used in ANTICOAGULANT THERAPY
  • acts on LIVER = IMPAIRS production of vit-K DEPENDENT factors (II, VII, IX, X “2790” and Protein C/ S/ Z)
  • Monitored by PT (INR= 2.0 - 3.0)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Fondaparinoux: what does it do ? How is it monitored ?

A
  • COMBINES with ENHANCES anti-thrombin activity
  • inhibits Xa
  • monitored by anti-Xa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Dabigatran: what does it do ? How is it monitored ?

A
  • DIRECT THROMBIN INHIBITOR (both free and clot-bound)
  • not monitored
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Direct Xa Inhibitors: what do they do ? How are they monitored ?

A
  • DIRECTLY INHIBITS Xa (free, bound to IXa, and clot-bound Xa)
  • monitored by anti-Xa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What is Thrombolytic Therapy ? Give examples.

A

Removes pathological clots:
- recombinant TPA & purified UROKINASE = treats MI, embolic/ thrombotic stroke, pulmonary embolisms
- STREPTOKINASE = plasminogen activator but can induce immune/ allergic response

TPA = Tissue Plasminogen Activator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Tube/ anticoagulant requirements for coagulation testing ?

A
  • Sodium citrate (light blue top)
  • Filled to capacity
  • 1:9 anticoagulant to blood
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Why is Sodium Citrate the preferred anticoagulant for coagulation testing ?

A
  1. Preserves V and VIII (labile factors)
  2. Stabilizes pH
  3. Does not inhibit PLT function
  4. Anticoagulant reversed when Ca2+ is added
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Interferences in Coagulation Testing

A
  • clotted samples
  • insufficient tube volume
  • EDTA collection
  • anticoagulants therapy (heparin, coumadin)
  • hemolysis
  • lipemia
  • cold temp
  • hot temp
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

How does cool temp storage interfere with coag testing ?

A

prematurely activates VII and PLTs during transport/ storage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

How does hot temp interfere with coag testing ?

A

deteriorates factors V and VIII (heat-labile)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

How does gross lipemia interfere with coag testing ?

A

interferes with testing that use end-point detection (PT, PTT, TT, Fibrinogen)
- increase turbidity = falsely decrease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

How does EDTA interfere with coag testing ?

A
  • EDTA does not preserve factor V
  • prolongs tests
  • chelates Ca2+ needed for coagulation cascade
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

How does insufficient tube volume interfere with coag testing ?

A

too much Sodium Citrate anticoagulant = tests falsely prolonged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

How does Turbidimetric End-point detection work in coag testing ?

A
  • fibrin clot forms = optical density increases/ transmittance decreases
  • when optical density > baseline = timer stops to indicate cot formation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

How does hemolysis interfere with coagulation testing ?

A
  • severe hemolysis = falsely decrease PT and PTT
  • coagulation prematurely starts before testing
  • check clots in hemolyzed samples
53
Q

Thrombocytopenia due to decreased/ defective production (3)

A
  1. Megakaryocyte hypoplasia:
    - inadequate megakaryocytes in BM
    - congenital (Fanconi’s), mutations, drugs, infection, injury to BM (radiation, chemotherapy)
  2. Replacement of BM with fibrosis
    - Primary Myelofibrosis or Hairy Cell
  3. Inadequate megakaryrocytes in PBS:
    - megaloblastic anemia (impaired DNA synthesis) or MDS
    - normal marrow but peripheral blood cytopenia
54
Q

Causes of Thrombocytopenia (3). Give examples.

A
  1. Defective Production (hypoplasia, PMF, MDS)
  2. Increased Consumption (TTP, HUS, DIC)
  3. Increased Destruction by Antibodies (ITP, Drug-induced, HIT)
55
Q

ITP

A

Idiopathic Thrombocytopenic Purpura:
- thrombocytopenia due to increased destruction
- IgG binds to PLT GPIa or IIIb/IIa (surface glycoproteins) = removed by spleen
- megakaryocyte fragments, Large PLTs (?increased BM production/ early BM release)

56
Q

Drug-Induced Thrombocytopenia

A
  1. Penicillin, quinidine
    - anti-drug Ab binds to PLT glycoproteins via Fab region IN THE PRESENCE OF DRUG
    - Fc region binds to Fc receptors on phagocytes = removal by spleen
  2. Procainamide, gold salts
    - autoAb bind to PLT glycoproteins WITHOUT drug present
57
Q

Heparin-Induced Thrombocytopenia (HIT)

A
  • type of Drug-induced Thrombocytopenia
  • (unfractioned) heparin binds to PF4 on PLT = conformational change exposes new epitopes = Ab formation against PF4/heparin complex
  • Fc region binds to PLT Fc receptors = activation and aggregation = decreased PLT count
58
Q

Which part of the anti-drug Ab causes PLT activation/ aggregation in HIT ?

A

Fc region = binds other PLTs = activation/ aggregation

59
Q

Cause of TTP

A

Thrombotic Thrombocytopenic Purpura:
- ADAMTS13 deficiency
- insufficient ADAMTS13 enzyme to cleave vWF multimers

60
Q

Cause of HUS

A

Hemolytic Uremic Syndrome:
- viral/ bacterial infection
Ie. Shigella or E. coli O:157

61
Q

Cause of DIC

A

Disseminated Intravascular Coagulation:
- secondary to systemic disease
Ie. infection, trauma, TRANSFUSION REACTION

62
Q

How to confirm TTP

A

Molecular genetic testing = ADAMTS13 deficiency
ADAMTS13 activity test
PBS = poly, schisto, sphero, nRBC

63
Q

How to confirm HUS

A

Blood culture = Shigella or E. coli O:157
PBS = poly, schisto, sphero, nRBC

64
Q

How to differentiate DIC from TTP and HUS

A

DIC:
Transfusion history
PBS = poly, schisto, NO SPHERO, nRBC
PT/ PTT = PROLONGED
Fibrinogen = decreased (clot formation)
D-dimer = increased (fibrinolysis)

NOTE: all will have decreased PLT, (PBS = poly, schisto)

65
Q

Differentiate ET from Reactive Thrombocytosis

A

Essential Thrombocytosis:
- stem cell disorder
- splenomegaly
- abnormal PLTs/ function
- clustering megakaryocytes in BM

Reactive Thrombocytosis:
- hemorrhage
- splenectomy

66
Q

What is Bernard Soulier Syndrome ?

A

Deficient/ defective GPIb from PLT surface
- PLTs cannot bind vWF = DEFECTIVE ADHESION

67
Q

Bernard Soulier Syndrome (PBS, BM, PT/PTT. PLT, BT, PLT aggregation)

A

PBS= giant PLTs
BM= normal/ increased megakaryocytes
PT/ PTT = normal
PLT = mild DECREASE
BT= increased (defective adhesion)

PLT aggregation:
ADP, EPO, collagen, a.a.= normal
Ristocetin= ABNORMAL

68
Q

What is Glanzmann’s Thrombasthenia

A

GPIIb/ IIIa deficient or defective
- PLTs cannot bind fibrinogen and vWF = DEFECTIVE AGGREGATION

69
Q

Inheritance pattern for Bernard Soulier and Glanzmann’s Thrombasthenia

A

Autosomal recessive

70
Q

Glanzmann’s Thrombasthenia (PBS, BM, PT/ PTT, PLT, BT, PLT aggregation)

A

PBS/ BM= normal PLTs and megakaryocytes
PT/PTT= normal
BT= increased (defective aggregation)

ADP, EPO, collagen, a.a.= abnormal
Ristocetin= normal

71
Q

Which coagulation disorder is associated with albinism ?

A

Dense granule deficiency

72
Q

What does Dense granule deficiency affect ?

A

PLT aggregation

73
Q

Alpha granule deficiency (PT/ PTT, PLT, BT)

A

PT/ PTT= normal
PLT= agranular, large, mild decrease
BT= increased (defective adhesion/ aggregation; primary hemostasis)

74
Q

Inheritance pattern of vWD. What is vWD ?

A

WonWillebrand Disease = AUTOSOMAL DOMINANT
- mutation of vWF gene= quantitative/ qualitative defect
- DEFECTIVE PLT ADHESION

75
Q

vWD (PT, PTT, PLT, BT, PLT aggregation). What other tests can be done ?

A

PT = normal
PTT = normal OR increased
PLT= normal
BT= increased (defective adhesion)

ADP, collagen, EPO, a.a.= normal
Ristocetin= abnormal

vWF antigen assay= decreased
FVIII assay = decreased (vWF needed to stabilize FVIII in plasma)

76
Q

vWD vs Bernard Soulier: Ristocetin cofactor assay results

A

vWD= abnormal (no vWF)
Bernard Soulier= normal (has vWF to bind GPIb receptors supplied by normal PLTs)

RECALL: Ristocetin cofactor assay tests patient plasma with NORMAL PLTs

77
Q

How does liver disease affect coagulation ?

A

Affects factors synthesized in liver:
- vit K dependent factors (II/ prothrombin, VII, IX, X, Protein C/S/Z)
- Dysfibrinogenemia

78
Q

Hemophilia A: cause and lab results (factor assay, PT, PTT, TT, BT)

A
  • FVIII deficiency
  • X-linked recessive

FVIII assay = decreased
PT= normal
PTT= abnormal
TT= normal
BT= normal

79
Q

Hemophilia B: cause and lab results (factor assay, PT, PTT, BT, TT)

A
  • Factor IX deficiency

FIX assay= DECREASED
PT= normal
PTT= INCREASED
BT= normal
TT= normal

80
Q

Hemophilia C: cause and lab results (factor assay, PT, PTT, BT, TT)

A
  • FXI deficiency

FXI assay= DECREASED
PT= normal
PTT= INCREASED
TT = normal

81
Q

Afibrinogenemia/hypofibrinogenemia: cause, effect and lab results

A
  • Fibrinogen < 0.5 g/L = autosomal recessive
  • PLT adhesion/ aggregation= abnormal

PT, PTT, TT, BT= INCREASED

82
Q

Dysfibrinogenemia: cause, effect, and lab results

A
  • AUTOSOMAL DOMINANT or acquired
  • ALTERED fibrinogen STRUCTURE = defective clot formation AND fibrinolysis
  • results in THROMBOPHILIA

PT= normal
PTT= normal
TT= INCREASED
Reptilase= MORE PROLONGED*

*NOTE: deformed fibrinogen can’t even bind to reptilase

83
Q

FXII deficiency: effects, and lab results (factor assay, PT, PTT, TT, BT)

A
  • no clinical bleeding

FXII assay= DECREASED
PT, TT, BT= normal
PTT= INCREASED

84
Q

HMWK or PK deficiency: cause, effects, and lab results (factor assay, PT, PTT, TT, BT)

A
  • no clinical bleeding

Factor assays= DECREASED
PT, TT, BT= normal
PTT= INCREASED

85
Q

Factors II, V, X deficiency: lab results (PT, PTT, TT, BT)

A
  • all are factors in common pathway

PT/, PTT= increased
TT, BT= normal

86
Q

FVII deficiency: lab results (PT, PTT, TT, BT)

A

PT= INCREASED
PTT, TT, BT= normal

87
Q

Factor XIII deficiency: clinical effects and lab testing ?

A
  • decreased formation of insoluble clots = defective wound healing
  • [XIII] measured by immunoassay/ chromogenic assay (NADPH consumption)

PT/ PTT= normal

88
Q

Factor V Leiden: cause, effect, and lab testing

A
  • AUTOSOMAL DOMINANT
  • mutation = arginine to glutamine
  • resistance to activated Protein C (aPC)= FV not inhibited despite high concentrations of thrombin = THROMBOPHILIA

Anticlot Protein C Resistance assay
Molecular genetics/ PCR

89
Q

Prothrombin G20210A mutation: cause, effect and lab testing

A
  • prothrombin gene = guanine to ADENINE
  • increased [prothrombin] = increased risk of thrombosis

Molecular genetics/ PCR

90
Q

Protein C/ S deficiency: cause, effects and lab testing

A
  • AUTOSOMAL DOMINANT or acquired
  • increased risk of Deep-Vein Thrombosis (DVT), pulmonary embolism and stroke
  • cutaenous hemorrhage, tissue NECROSIS, and DIC

Clot based assay
Antigenic assay to measure levels

91
Q

Lupus Anticoagulant Syndrome: cause and clinical effects

A
  • anti-phospholipid autoAb form = bind to phospholipids (PF3) in PTT reagent = interferes with prothrombin activation
  • PROLONGS COAG TESTING
92
Q

Lupus Anticoagulant Syndrome: lab results (PT, PTT, TT, Mixing Studies, DRVVT)

A

PT= normal
PTT= INCREASED
TT= normal
Mixing studies= no correction with normal plasma
DRVVT= POSITIVE

DRVVT= Dilute Russel Viper Venom Time

93
Q

DRVVT: principle

A
  • viper venom activates factor X
  • reagent has low [phospholipid]

PROLONGED/ POSITIVE= Lupus Anticoagulant (LAC) in patient plasma interferes with prothrombin activation

Normal= no LAC

94
Q

Follow-up testing after POSITIVE DRVVT

A
  1. Use reagent with EXCESS PHOSPHOLIPIDS to neutralize LAC = normal clotting time = LAC positive
  2. Mixing study 1:1 of patient plasma and Normal plasma = uncorrected = LAC positive
95
Q

Which of the following would lead to a prolonged bleeding time?

a.
A platelet count of 155 x 10^9/L

b.
Von Willebrand disease

c.
Fibrinogen value of 1.2 g/L

d.
Hemophilia A

A

b.
Von Willebrand disease

96
Q

Prolonged PT and PTT: DIC, primary/ hyper fibrinoloysis, both or neither ?

A

DIC and hyper/primary fibrinoloysis

97
Q

Increased D-dimers: DIC, primary/ hyper fibrinoloysis, both or neither ?

A

DIC and hyper/primary fibrinoloysis

98
Q

Elevated plasmin: DIC, primary fibrinoloysis, both or neither ?

A

DIC and hyper/primary fibrinoloysis

99
Q

Platelet count is normal: DIC, primary/ hyper fibrinoloysis, both or neither ?

A

ONLY hyperfibrinolytic states (primary fibrinolysis)

100
Q

Factor XIII levels are elevated: DIC, primary fibrinoloysis, both or neither ?

A

Neither

101
Q

Schistocytes can be seen on the smear: DIC, primary fibrinoloysis, both or neither ?

A

ONLY Disseminated Intravascular Coagulation (DIC)

102
Q

Fibrinogen degradation products are elevated: DIC, primary fibrinoloysis, both or neither ?

A

Both

103
Q

Which of the following is true about the aPTT test?

a.
It will be abnormal with a factor XIII deficiency

b.
It is used to monitor coumadin therapy

c.
It will be prolonged with abnormal platelet function

d.
It will be prolonged in Von Willebrand deficiency

A

d.
It will be prolonged in Von Willebrand deficiency

104
Q

Thrombocytopenia on PBS: HUS, TTP, both or neither ?

A

Both

105
Q

Most commonly in children: HUS, TTP, both or neither ?

A

ONLY Thrombotic Thrombocytopenic Purpura (TTP)

106
Q

Can be congenital or acquired: HUS, TTP, both or neither ?

A

ONLY Thrombotic Thrombocytopenic Purpura (TTP)

107
Q

Microangiopathic hemolytic anemia with schisto and poly: HUS, TTP, both or neither ?

A

Both

108
Q

Clotting factors are decreased (used up): HUS, TTP, both or neither ?

A

Neither

109
Q

Toxins damage renal glomerular capillaries: HUS, TTP, both or neither ?

A

ONLY Hemolytic Uremic Syndrome (HUS)

110
Q

Abnormally large vWF multimers are implicated: HUS, TTP, both or neither ?

A

ONLY Thrombotic Thrombocytopenic Purpura (TTP)

111
Q

Autoantibodies to ADAMTS 13 can occur: HUS, TTP, both or neither ?

A

ONLY Thrombotic Thrombocytopenic Purpura (TTP)

112
Q

Prolonged PT and APTT: HUS, TTP, both or neither ?

A

Neither

113
Q

Which of the following can cause a prolonged APTT?

a.
Decreased levels of factor XIII

b.
Decreased levels of factor VII

c.
Decreased levels of factor XI

d.
In-vitro hemolysis

A

c.
Decreased levels of factor XI

114
Q

Crit: PLT

A

inpatient: <10 x10^9/L
outpatient: <20 x10^9/L

115
Q

Crit: PTT

A

> 120 sec

116
Q

Crit: Fibrinogen

A
117
Q

Which statement about the fibrinogen assay is most correct?

a.
Clotting time is proportional to the amount of thrombin in the plasma

b.
An abnormal result is seen in patients on heparin therapy

c.
Concentrated thrombin reagent is added to dilute plasma

d.
Patient plasma is mixed 1:1 with fibrinogen-deficient plasma

A

c.
Concentrated thrombin reagent is added to dilute plasma

118
Q
  1. Mode of action of heparin as an anticoagulant in the human body
  2. List which coagulation factors are inhibited by UFH
A
    • Heparin is a cofactor for Antithrombin
    • Heparin binds to AT, changes its conformation, and accelerates the rate of inactivation of coagulation factors by AT
  2. UFH inhibits all the serine proteases except VII and Kallikrein
    - serine proteases: XIIa, XIa, IXa, Xa and IIa (and plasmin)
119
Q

Which of the following can be ruled out if a patient has a D-dimer result of 8.0 mg/L?

a.
Disseminated intravascular coagulation

b.
Deep Vein thrombosis

c.
Pulmonary embolism

d.
None of the above

A

d.
None of the above

120
Q

Thrombocytosis is typically seen in which of the following?

a.
Acute leukemia

b.
Post-splenectomy

c.
Essential Thrombocythemia

d.
Ineffective thrombopoiesis

A

b.
Post-splenectomy

c.
Essential Thrombocythemia

121
Q

In heparin-induced thrombocytopenia (HIT), patients on heparin develop antibodies to:

a.
Self platelet Fc receptor antigens, causing platelet activation

b.
Phospholipids, which interferes with the activation of thrombin

c.
pf3, which causes PLT aggregation and activation

d.
Heparin in complex with pf4, leading to activation

A

d.
Heparin in complex with pf4, leading to activation

122
Q

A patient specimen is received from an outside laboratory for coagulation testing. The history provided indicates the patient is on Coumadin (warfarin). The following results are obtained:

PT: no clot detected

PTT: no clot detected

The specimen is retested and the results check. You bring the results to your supervisor, who instructs you to perform a fibrinogen assay. Will the fibrinogen assay be useful?

A

Yes. A fibrinogen assay would be useful. The patients history indicates coumadin therapy and coumadin acts by inhibiting fibrinogen function

123
Q

Which clotting factors would be affected by coumadin therapy? Select all that apply:

a.
Factor XIII

b.
Factor V

c.
Factor VIII

d.
Factor IX

A

d.
Factor IX

124
Q

A Bleeding Time of >9 minutes could be expected in which of the following disorders? Select all that apply:

a.
Abnormal vascular function

b.
Marked thrombocytopenia

c.
Glanzman’s thrombasthenia

d.
Hemophilia A

A

a.
Abnormal vascular function

b.
Marked thrombocytopenia

c.
Glanzman’s thrombasthenia

125
Q

How is the fibrinogen concentration of a sample determined in the fibrinogen assay?

A

The instrument compares the clotting time to a calibration curve

126
Q

Which statement about the quantitative D-dimer assay is correct?

a.
The normal reference range is >0.5 g/L

b.
The result is abnormal when FDP’s are decreased

c.
Micro-latex particles in the reagent are coated with monoclonal antibodies to D-dimer

d.
The presence of D-dimers is detected by clot formation

A

c.
Micro-latex particles in the reagent are coated with monoclonal antibodies to D-dimer

127
Q

In the APTT test, what happens during the initial incubation after the APTT reagent is added to the test plasma?

a.
Factor VII and the extrinsic pathway are activated

b.
Factors IX and VIII are activated

c.
Factor XI and XII are activated

d.
Factor X and V are activated

A

c.
Factor XI and XII are activated

128
Q

Which of the following is correct with respect to specimen collection for coagulation testing?

a.
Mix the sample well with vigor

b.
Draw coagulation specimens after an EDTA tube

c.
Use a 1:9 dilution of anticoagulant to blood

d.
Make sure the vacutainer tube is filled 70% capacity

A

c.
Use a 1:9 dilution of anticoagulant to blood

129
Q

Follow-up for Hct > 0.55 L/L

A
  • there is excess anticoagulant = extra citrate will bind the calcium in the test reagent and falsely prolong the clotting time
  • specimen should be recollected with less anticoagulant and the tests repeated

MLSCI330 Hematology (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions